• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology
【2h】

Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology

机译：通过与胰腺腺癌病理生理学相关的常规临床标志物的联合使用，可改善黄疸和非黄疸型胰腺癌患者的胰腺腺癌诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundThere is still no reliable biomarker for the diagnosis of pancreatic adenocarcinoma. Carbohydrateantigen 19–9 (CA 19–9) is a tumor marker only recommended for pancreatic adenocarcinomafollow-up. One of the clinical problems lies in distinguishing between thiscancer and other benign pancreatic diseases such as chronic pancreatitis. In this study wewill assess the value of panels of serum molecules related to pancreatic cancer physiopathologyto determine whether alone or in combination could help to discriminate betweenthese two pathologies.MethodsCA 19–9, carcinoembryonic antigen (CEA), C-reactive protein, albumin, insulin growth factor-1 (IGF-1) and IGF binding protein-3 were measured using routine clinical analyzers in acohort of 47 pancreatic adenocarcinoma, 20 chronic pancreatitis and 15 healthy controls.ResultsThe combination of CA 19–9, IGF-1 and albumin resulted in a combined area under thecurve (AUC) of 0.959 with 93.6% sensitivity and 95% specificity, much higher than CA 19–9alone. An algorithm was defined to classify the patients as chronic pancreatitis or pancreaticcancer with the above specificity and sensitivity. In an independent validation group of 20 pancreatic adenocarcinoma and 13 chronic pancreatitis patients, the combination of the four molecules classified correctly all pancreatic adenocarcinoma and 12 out of 13 chronic pancreatitis patients.ConclusionsAlthough this panel of markers should be validated in larger cohorts, the high sensitivity andspecificity values and the convenience to measure these parameters in clinical laboratoriesshows great promise for improving pancreatic adenocarcinoma diagnosis
机译：背景技术目前尚无可靠的生物标志物可用于胰腺癌的诊断。碳水化合物抗原19–9（CA 19–9）是仅推荐用于胰腺腺癌随访的肿瘤标志物。临床问题之一在于区分该癌症与其他良性胰腺疾病，例如慢性胰腺炎。在这项研究中，我们将评估与胰腺癌生理病理学相关的血清分子检测小组的价值，以确定是单独还是联合使用可以帮助区分这两种病理学。方法CA 19–9，癌胚抗原（CEA），C反应蛋白，白蛋白，胰岛素使用常规临床分析仪对47例胰腺腺癌，20例慢性胰腺炎和15例健康对照者的队列中的生长因子-1（IGF-1）和IGF结合蛋白3进行了测定。结果CA 19-9，IGF-1和白蛋白的组合在曲线下的合并区域（AUC）为0.959，灵敏度为93.6％，特异性为95％，远高于单独的CA 19-9。定义了一种算法，将具有上述特异性和敏感性的患者分类为慢性胰腺炎或胰腺癌。在一个独立的20例胰腺腺癌和13例慢性胰腺炎患者的验证组中，这四种分子的组合正确分类了所有胰腺腺癌和13例慢性胰腺炎患者中的12例。特异性值和在临床实验室中方便地测量这些参数显示出改善胰腺癌诊断的巨大希望

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号